Search results
Showing 8101 to 8115 of 8904 results
This guideline has been updated and replaced by NICE guideline CG137.
This guidance has been withdrawn.
Clopidogrel in the treatment of non-ST-segment-elevation acute coronary syndrome (TA80)
This guidance has been replaced by recommendations 1.3.4 to 1.3.8 in NICE guideline CG94 and by recommendation 1.3.18 in NICE guideline CG172.
Selpercatinib for treating advanced thyroid cancer with RET alterations (TA742)
This guidance has been updated and replaced by NICE technology appraisal guidance 1038.
Crizanlizumab for preventing sickle cell crises in sickle cell disease (TA743)
NICE has withdrawn this guidance. Novartis will stop marketing crizanlizumab (Adakveo) because its marketing authorisation has been withdrawn by the Medicines and Healthcare products Regulatory Agency (MHRA). Novartis has issued a direct letter to healthcare professionals specialising in haematology. No new people will start taking crizanlizumab in the UK. Healthcare professionals should discuss alternative treatment options with people currently having crizanlizumab.
November 2011 On 25 October 2011, Eli Lilly and Company announced the withdrawal of its Xigris (drotrecogin alfa [activated]) product in all markets following results of the PROWESS–SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients with septic shock. The company is working with regulatory agencies on this withdrawal, and is in the process of notifying healthcare professionals and clinical trial investigators. As a result of this, NICE has withdrawn its guidance on the use of drotrecogin alfa (activated) for severe sepsis.
Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis (TA756)
This guidance has been updated and replaced by NICE technology appraisal guidance 1018.
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA759)
This guidance has been updated and replaced by NICE technology appraisal guidance 835.
This guideline has been updated and replaced by NICE guideline CG137.
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (TA760)
This guidance has been updated and replaced by NICE technology appraisal guidance TA1042
This guidance has been updated and replaced by NICE technology appraisal guidance 1043.
This guidance has been updated and replaced by NICE technology appraisal guidance 1040.
This guidance has been updated and replaced by NICE technology appraisal guidance 1045.
This guidance has been updated and replaced by NICE technology appraisal guidance 1054.
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (TA823)
This guidance has been updated and replaced by NICE technology appraisal guidance 1071.